Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Gosai, Sager J ^a   Kwak, Joon Hyeok ^a   Luke, Cliff J ^a   Long, Olivia S ^a   King, Dale E ^a   Kovatch, Kevin J ^a   Johnston, Paul A ^b   Shun, Tong Ying ^b   Lazo, John S ^b   Perlmutter, David H ^a   Silverman, Gary A ^a   Pak, Stephen C ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SERINE PROTEINASE INHIBITOR; TRYPSIN INHIBITOR; ALPHA 1 ANTITRYPSIN; CANTHARIDIN; DOPAMINE RECEPTOR BLOCKING AGENT; ENZYME INHIBITOR; FLUPHENAZINE; PHOTOPROTEIN; PIMOZIDE; SODIUM AZIDE;

ANIMAL CELL; ARTICLE; AUTOMATION; AUTOPHAGY; CAENORHABDITIS ELEGANS; CELL THERAPY; CELL VIABILITY; CONTROLLED STUDY; DRUG SCREENING; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; NONHUMAN; PHENOTYPE; PROTEIN AGGREGATION; QUALITATIVE ANALYSIS; QUALITY CONTROL; TISSUE GROWTH; TRANSGENIC ANIMAL; ANIMAL; ANIMAL MODEL; CELL SURVIVAL; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; METHODOLOGY;

ANIMALIA; CAENORHABDITIS ELEGANS;

ALPHA 1-ANTITRYPSIN; ANIMALS; AUTOPHAGY; CAENORHABDITIS ELEGANS; CANTHARIDIN; CELL SURVIVAL; DOPAMINE ANTAGONISTS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FLUPHENAZINE; HUMANS; LUMINESCENT PROTEINS; MICROSCOPY, FLUORESCENCE; MODELS, ANIMAL; PIMOZIDE; SODIUM AZIDE;

EID: 78649757232     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015460     Document Type: Article

References (69)

1. Aguzzi A, O'Connor T (2010) Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 9: 237-248.
2. Herczenik E, Gebbink MF (2008) Molecular and cellular aspects of protein misfolding and disease. FASEB J 22: 2115-2133.
3. Krebs MP, Holden DC, Joshi P, Clark CL, 3rd, Lee AH, et al. (2010) Molecular mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue. J Mol Biol 395: 1063-1078.
4. Lomas DA, Belorgey D, Mallya M, Miranda E, Kinghorn KJ, et al. (2005) Molecular mousetraps and the serpinopathies. Biochem Soc Trans 33: 321-330.
5. Picken MM (2010) Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med 134: 545-551.
6. Balch WE, Morimoto RI, Dillin A, Kelly JW (2008) Adapting proteostasis for disease intervention. Science 319: 916-919.
7. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A (2006) Opposing activities protect against age-onset proteotoxicity. Science 313: 1604-1610.
8. Bartolini M, Andrisano V (2010) Strategies for the inhibition of protein aggregation in human diseases. Chembiochem 11: 1018-1035.
9. Krainc D (2010) Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases. Arch Neurol 67: 388-392.
10. Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, et al. (2010) An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 329: 229-232.
11. Link CD (2006) C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Exp Gerontol 41: 1007-1013.
12. Frearson JA, Collie IT (2009) HTS and hit finding in academia - from chemical genomics to drug discovery. Drug Discov Today 14: 1150-1158.
13. Mayr LM, Bojanic D (2009) Novel trends in high-throughput screening. Curr Opin Pharmacol 9: 580-588.
14. Bleicher KH, Bohm HJ, Muller K, Alanine AI (2003) Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2: 369-378.
15. Hodgson J (2001) ADMET-turning chemicals into drugs. Nat Biotechnol 19: 722-726.
16. Gleeson MP (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 51: 817-834.
17. Gleeson P, Bravi G, Modi S, Lowe D (2009) ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters. Bioorg Med Chem 17: 5906-5919.
18. Giuliano KA, Johnston PA, Gough A, Taylor DL (2006) Systems cell biology based on high-content screening. Methods Enzymol 414: 601-619.
19. Haney SA, LaPan P, Pan J, Zhang J (2006) High-content screening moves to the front of the line. Drug Discov Today 11: 889-894.
20. Johnston PA (2002) Cellular platforms for HTS: three case studies. Drug Discov Today 7: 353-363.
21. Johnston PA, Foster CA, Tierno MB, Shun TY, Shinde SN, et al. (2009) Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Assay Drug Dev Technol 7: 250-265.
22. Johnston PA, Phillips J, Shun TY, Shinde S, Lazo JS, et al. (2007) HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol 5: 737-750.
23. Johnston PA, Soares KM, Shinde SN, Foster CA, Shun TY, et al. (2008) Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol 6: 505-518.
24. Nickischer D, Laethem C, Trask OJ, Jr., Williams RG, Kandasamy R, et al. (2006) Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation. Methods Enzymol 414: 389-418.
25. Trask OJ, Jr., Baker A, Williams RG, Nickischer D, Kandasamy R, et al. (2006) Assay development and case history of a 32K-biased library high-content MK2-EGFP translocation screen to identify p38 mitogen-activated protein kinase inhibitors on the ArrayScan 3.1 imaging platform. Methods Enzymol 414: 419-439.
26. Williams RG, Kandasamy R, Nickischer D, Trask OJ, Jr., Laethem C, et al. (2006) Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors. Methods Enzymol 414: 364-389.
27. Stockwell BR (2000) Chemical genetics: ligand-based discovery of gene function. Nat Rev Genet 1: 116-125.
28. Breger J, Fuchs BB, Aperis G, Moy TI, Ausubel FM, et al. (2007) Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog 3: e18.
29. Kwok TC, Ricker N, Fraser R, Chan AW, Burns A, et al. (2006) A small-molecule screen in C. elegans yields a new calcium channel antagonist. Nature 441: 91-95.
30. Molina G, Vogt A, Bakan A, Dai W, Queiroz de Oliveira P, et al. (2009) Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol 5: 680-687.
31. Moy TI, Conery AL, Larkins-Ford J, Wu G, Mazitschek R, et al. (2009) High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem Biol 4: 527-533.
32. North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, et al. (2007) Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447: 1007-1011.
33. Petrascheck M, Ye X, Buck LB (2007) An antidepressant that extends lifespan in adult Caenorhabditis elegans. Nature 450: 553-556.
34. Rihel J, Prober DA, Arvanites A, Lam K, Zimmerman S, et al. (2010) Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science 327: 348-351.
35. Tran TC, Sneed B, Haider J, Blavo D, White A, et al. (2007) Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res 67: 11386-11392.
36. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, et al. (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4: 33-41.
37. Artal-Sanz M, de Jong L, Tavernarakis N (2006) Caenorhabditis elegans: a versatile platform for drug discovery. Biotechnol J 1: 1405-1418.
38. de Voer G, Peters D, Taschner PE (2008) Caenorhabditis elegans as a model for lysosomal storage disorders. Biochim Biophys Acta 1782: 433-446.
39. Kaletta T, Hengartner MO (2006) Finding function in novel targets: C. elegans as a model organism. Nat Rev Drug Discov 5: 387-398.
40. Silverman GA, Luke CJ, Bhatia SR, Long OS, Vetica AC, et al. (2009) Modeling molecular and cellular aspects of human disease using the nematode Caenorhabditis elegans. Pediatr Res 65: 10-18.
41. Lee S, Howell BJ (2006) High-content screening: emerging hardware and software technologies. Methods Enzymol 414: 468-483.
42. Morley JF, Brignull HR, Weyers JJ, Morimoto RI (2002) The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A 99: 10417-10422.
43. Lum JJ, DeBerardinis RJ, Thompson CB (2005) Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 6: 439-448.
44. Melendez A, Talloczy Z, Seaman M, Eskelinen EL, Hall DH, et al. (2003) Autophagy genes are essential for dauer development and life-span extension in C. elegans. Science 301: 1387-1391.
45. Kang C, You YJ, Avery L (2007) Dual roles of autophagy in the survival of Caenorhabditis elegans during starvation. Genes Dev 21: 2161-2171.
46. Driscoll M, Chalfie M (1991) The mec-4 gene is a member of a family of Caenorhabditis elegans genes that can mutate to induce neuronal degeneration. Nature 349: 588-593.
47. Royal DC, Bianchi L, Royal MA, Lizzio M, Jr., Mukherjee G, et al. (2005) Temperature-sensitive mutant of the Caenorhabditis elegans neurotoxic MEC-4(d) DEG/ENaC channel identifies a site required for trafficking or surface maintenance. J Biol Chem 280: 41976-41986.
48. Luke CJ, Pak SC, Askew YS, Naviglia TL, Askew DJ, et al. (2007) An intracellular serpin regulates necrosis by inhibiting the induction and sequelae of lysosomal injury. Cell 130: 1108-1119.
49. Gill MS, Olsen A, Sampayo JN, Lithgow GJ (2003) An automated high-throughput assay for survival of the nematode Caenorhabditis elegans. Free Radic Biol Med 35: 558-565.
50. Nehrke K (2003) A reduction in intestinal cell pHi due to loss of the Caenorhabditis elegans Na+/H+ exchanger NHX-2 increases life span. J Biol Chem 278: 44657-44566.
51. Perlmutter DH (2002) Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. Journal of Clinical Investigation 110: 1579-1583.
52. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
53. Giacomotto J, Segalat L (2010) High-throughput screening and small animal models, where are we? Br J Pharmacol 160: 204-216.
54. Szewczyk NJ, Kozak E, Conley CA (2003) Chemically defined medium and Caenorhabditis elegans. BMC Biotechnol 3: 19-25.
55. Ellerbrock BR, Coscarelli EM, Gurney ME, Geary TG (2004) Screening for presenilin inhibitors using the free-living nematode, Caenorhabditis elegans. J Biomol Screen 9: 147-152.
56. Okoli I, Coleman JJ, Tampakakis E, An WF, Holson E, et al. (2009) Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. PLoS One 4: e7025.
57. Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, et al. (2008) Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat Chem Biol 4: 295-305.
58. Zhang L, Yu J, Pan H, Hu P, Hao Y, et al. (2007) Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci U S A 104: 19023-19028.
59. Kamimoto T, Shoji S, Hidvegi T, Mizushima N, Umebayashi K, et al. (2006) Intracellular inclusions containing mutant alpha1-antitrypsin Z are propagated in the absence of autophagic activity. J Biol Chem 281: 4467-4476.
60. Link CD (1995) Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A 92: 9368-9372.
61. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, et al. (2003) Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A 100: 9980-9985.
62. Lakso M, Vartiainen S, Moilanen AM, Sirvio J, Thomas JH, et al. (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 86: 165-172.
63. Faber PW, Alter JR, MacDonald ME, Hart AC (1999) Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci U S A 96: 179-184.
64. Oeda T, Shimohama S, Kitagawa N, Kohno R, Imura T, et al. (2001) Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in transgenic Caenorhabditis elegans. Hum Mol Genet 10: 2013-2023.
65. Nehrke K, Melvin JE (2002) The NHX family of Na+-H+ exchangers in Caenorhabditis elegans. J Biol Chem 277: 29036-29044.
66. Johnston PA, Foster CA, Shun TY, Skoko JJ, Shinde S, et al. (2007) Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay Drug Dev Technol 5: 319-332.
67. Brideau C, Gunter B, Pikounis B, Liaw A (2003) Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen 8: 634-647.
68. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R (2006) Statistical practice in high-throughput screening data analysis. Nat Biotechnol 24: 167-175.
69. Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG (2000) Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol 18: 538-543.